Brand family
Erzofri extended-release
Paliperidone palmitate · Shandong Luye Pharmaceutical
United States
- Presentations
- 6
- Markets
- 1
Erzofri extended-release is a brand of Paliperidone palmitate marketed by Shandong Luye Pharmaceutical, with 6 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Paliperidone palmitate
- Brand owner
- Shandong Luye Pharmaceutical
- Registered in
- United States
- Strengths and forms
- 117 mg/0.75 mL injection, 156 mg/1 mL injection, 234 mg/1.5 mL injection, 351 mg/2.25 mL injection, 39 mg/0.25 mL injection, 78 mg/0.5 mL injection
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Erzofri extended-release 117 mg/0.75 mL injectionIntramuscular | Shandong Luye Pharmaceutical | US FDA | Available on request |
| Erzofri extended-release 156 mg/1 mL injectionIntramuscular | Shandong Luye Pharmaceutical | US FDA | Available on request |
| Erzofri extended-release 234 mg/1.5 mL injectionIntramuscular | Shandong Luye Pharmaceutical | US FDA | Available on request |
| Erzofri extended-release 351 mg/2.25 mL injectionIntramuscular | Shandong Luye Pharmaceutical | US FDA | Available on request |
| Erzofri extended-release 39 mg/0.25 mL injectionIntramuscular | Shandong Luye Pharmaceutical | US FDA | Available on request |
| Erzofri extended-release 78 mg/0.5 mL injectionIntramuscular | Shandong Luye Pharmaceutical | US FDA | Available on request |
Equivalent brands
Other brands of Paliperidone palmitate.
Brand names and trademarks belong to their owners and are used only to identify products.
Request Erzofri extended-release
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.